Development of multivalent CAR T cells as dual immunotherapy and conditioning agents

Hematopoietic stem cell transplantation (HSCT) is the only definitive cure for pediatric acute myeloid leukemia (AML). Despite adjustments in HSCT protocols and improvements in supportive care, 30% of high-risk patients who receive HSCT as part of their therapy still experience disease relapse with...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Quenton Rashawn Bubb, Mohammad Balood, Gabe Eduardo Seir, Leah Swartzrock, Ethan Haslett, Katie Ho, Peng Xu, Saida G. Wiltz, Elena Sotillo, Tanja A. Gruber, Rebecca M. Richards, Crystal L. Mackall, Agnieszka Czechowicz
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-03-01
Edice:	Molecular Therapy: Oncology
Témata:	MT: Regular Issue CAR-T AML pediatric AML HSCT trispecific
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S295032992500013X
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!